| Safety/PK component | POC component |  | ||
---|---|---|---|---|---|
 | Maraviroc 150 mg BID (n= 8) | Maraviroc 300 mg BID (n= 8) | Placebo (n= 33) | Maraviroc 300 mg BID (n= 77) | Pvaluea |
Female, number (percentage) | 4 (50.0) | 5 (62.5) | 22 (66.7) | 71 (92.2) | 0.0014 |
Age in years | Â | Â | Â | Â | Â |
   Mean (SD) | 58.5 (7.8) | 56.6 (5.9) | 53.4 (11.1) | 53.6 (12.1) | 0.9274 |
   Range | 44-67 | 46-63 | 34-76 | 20-81 | - |
Race, number (percentage) | Â | Â | Â | Â | - |
   White | 8 (100.0) | 8 (100.0) | 21 (63.6) | 51 (66.2) |  |
   Black | 0 | 0 | 0 | 3 (3.9) |  |
   Asian | 0 | 0 | 5 (15.2) | 7 (9.1) |  |
   Other | 0 | 0 | 7 (21.2) | 16 (20.8) |  |
Weight in kg, mean (SD) | 90.9 (30.4) | 88.9 (13.9) | 72.7 (16.9) | 70.5 (15.4) | 0.5173 |
Height in cm, mean (SD) | 164.5 (11.1) | 167.4 (4.8) | 162.0 (9.7) | 159.8 (7.6) | 0.2057 |
BMI in kg/m2, mean (SD) | 33.3 (10.2) | 31.6 (4.0) | 27.6 (5.5) | 27.5 (5.4) | 0.9670 |
Duration from first diagnosisb | Â | Â | Â | Â | 0.9817 |
   Mean in years | 11.0 | 11.9 | 7.8 | 7.9 |  |
   Range in years | 3.0-22.3 | 2.5-29.0 | 0.6-32.0 | 0.4-40.0 |  |
ACR components, mean (SD)c | Â | Â | Â | Â | Â |
   Tender/painful joint count | - | - | 17.5 (6.6) | 16.4 (7.3) | 0.3565 |
   Swollen joint count | - | - | 12.8 (5.9) | 11.5 (4.6) | 0.2062 |
   Patient's assessment of arthritis pain | - | - | 57.9 (26.0) | 59.3 (20.6) | 0.6375 |
   Patient's global assessment of arthritis | - | - | 61.8 (26.1) | 61.3 (21.2) | 0.8932 |
   Physician's global assessment of arthritis | - | - | 3.5 (0.7) | 3.5 (0.7) | 0.7926 |
   HAQ-DI | - | - | 1.7 (0.7) | 1.7 (0.6) | 0.8405 |
   CRP | - | - | 17.4 (19.0) | 14.3 (13.2) | 0.6946 |
DAS28-4 (CRP)c | - | - | 6.0 (0.9) | 5.8 (0.8) | 0.4554 |